Can a chelation treatment ease symptoms of gadolinium buildup?
NCT ID NCT06269055
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study from Stanford University looked at whether a chelation treatment using Ca-DTPA and Zn-DTPA can help people with gadolinium deposition disease, a condition where gadolinium from MRI contrast dye builds up in the body. Researchers interviewed 30 adults who had received at least five treatment sessions to see if their symptoms improved and what side effects occurred. The goal was to understand the potential benefits and risks of this approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Calcium Diethylenetriamine pentaacetate (Ca-DTPA) and Zinc Diethylenetriamine pentaacetate (Zn-DTPA)
- What this could lead to
- If successful, this could point toward a treatment that eases symptoms of gadolinium deposition disease.
- What could go wrong
- This is a small, completed study with only 30 participants, so results may not apply to everyone. Side effects from chelation therapy are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CA-DTPA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University Medical Center
Stanford, California, 94305, United States